Bor-Wen Wu
Overview
Explore the profile of Bor-Wen Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang K, Chiang N, Wu S, Yen C, Chen S, Yeh Y, et al.
Oncoimmunology
. 2021 Jul;
10(1):1943253.
PMID: 34290906
Background: Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and enhances the therapeutic efficacy...
2.
Hall P, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, et al.
Clin Cancer Res
. 2019 Feb;
25(9):2708-2716.
PMID: 30796035
Purpose: Patients with recurrent high-grade gliomas (HGG) are usually managed with alkylating chemotherapy ± bevacizumab. However, prognosis remains very poor. Preclinically, we showed that HGGs are a target for arginine...
3.
Beddowes E, Spicer J, Chan P, Khadeir R, Corbacho J, Repana D, et al.
J Clin Oncol
. 2017 Apr;
35(16):1778-1785.
PMID: 28388291
Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this...
4.
Szlosarek P, Steele J, Nolan L, Gilligan D, Taylor P, Spicer J, et al.
JAMA Oncol
. 2016 Sep;
3(1):58-66.
PMID: 27584578
Importance: Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not...
5.
Allen M, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, et al.
Cancer Res
. 2013 Nov;
74(3):896-907.
PMID: 24285724
Targeted therapies have yet to have significant impact on the survival of patients with bladder cancer. In this study, we focused on the urea cycle enzyme argininosuccinate synthetase 1 (ASS1)...
6.
Ott P, Carvajal R, Pandit-Taskar N, Jungbluth A, Hoffman E, Wu B, et al.
Invest New Drugs
. 2012 Aug;
31(2):425-34.
PMID: 22864522
Background Arginine deiminase (ADI) is an enzyme that degrades arginine, an amino acid that is important for growth and development of normal and neoplastic cells. Melanoma cells are auxotrophic for...